Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II triplet therapy study of binimetinib, lapatinib, and vinorelbine in RAS-mutated metastatic colorectal cancer
NL-OMON54073Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of binimetinib, lapatinib and vinorelbine in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Dose-limiting toxicities leading to RP2D and Best overall response within 6 months. Started Aug 2020; status: recruiting.
02
Drugs
binimetiniblapatinibvinorelbine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON54073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54073.